Controlled double-blind trial on the clinical effects of the chenodeoxycholic acid-fentonium bromide combination in the symptomatic treatment of biliary spastic-dyskinetic conditions.
A double-blind controlled trial was carried out to compare the effects of chenodeoxycholic acid combined with fentonium bromide (respectively, 125 and 20 mg for each capsule) vs. biliary acid alone in the treatment of biliary dyskinetic conditions with or without gallstones. Observations, concerning altogether 30 patients, showed a significantly higher and quicker efficacy of the combination (3--4 capsules daily during 14 days), in comparison to chenodeoxycholic acid alone, on the group of "painful" symptoms; on the contrary, no significant difference was noticed with regard to efficacy on "dyspeptic" symptoms. These results show the significant contribution of fentonium bromide and give experimental evidence of the usefulness and therapeutical advantages of the preparation under study.
D000328:Adult; D000368:Aged; D001286:Atropine Derivatives / Q000627:therapeutic use*; D001660:Biliary Tract Diseases / Q000188:drug therapy*; D002635:Chenodeoxycholic Acid / Q000494:pharmacology / Q000627:therapeutic use*; D002986:Clinical Trials as Topic; D003085:Colic / Q000188:drug therapy; D004063:Digestion / Q000187:drug effects; D004338:Drug Combinations; D004341:Drug Evaluation; D004357:Drug Synergism; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D013035:Spasm / Q000188:drug therapy*
D001286:Atropine Derivatives; D004338:Drug Combinations; D002635:Chenodeoxycholic Acid